Health Care, Pharmaceuticals, Biotech
Nov. 4, 2026
Can FDA-approved generic drugs still trigger manufacturing defect lawsuits?
For California attorneys, the distinction between regulatory approval and manufacturing compliance can determine whether a generic drug claim survives federal preemption--and whether the evidence connects a defect to injury.
When a patient experiences an unexpected treatment failure after receiving a generic medication, identifying the cause can be difficult. The drug may have met federal approval requirements, yet questions remain about whether the product dispensed was manufactured according to those standards. For attorneys, that distinction can determine whether a product liability claim survives federal preemption.
The issue is gaining relevance as generic competition expands. The U.S. Food and Dr...
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$895, but save $100 when you subscribe today… Just $795 for the first year!
Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)
Already a subscriber?
Sign In